Myovant Sciences Ltd MYOV:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/26/21 EST
22.45quote price arrow down-0.01 (-0.04%)
Volume
23,142
Close
22.46UNCH (UNCH)
Volume
473,367
52 week range
5.98 - 30.90

...

Loading . . .

KEY STATS

  • Open21.99
  • Day High22.62
  • Day Low21.38
  • Prev Close22.46
  • 52 Week High30.90
  • 52 Week High Date12/28/20
  • 52 Week Low5.98
  • 52 Week Low Date03/16/20
  • Market Cap2.039B
  • Shares Out90.80M
  • 10 Day Average Volume0.88M
  • Dividend-
  • Dividend Yield-
  • Beta2.97
  • 1 Year % Change133.71

RATIOS/PROFITABILITY

  • EPS (TTM)-2.66
  • P/E (TTM)-8.43
  • Fwd P/E (NTM)-9.04
  • EBITDA (MRQ)-245.662M
  • ROE (MRQ)-622.01%
  • Revenue (MRQ)34.71M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-687.61%
  • Debt To Equity (MRQ)-115.90%

EVENTS

  • Earnings Date05/17/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Myovant Sciences Ltd News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the...
Myrtle Potter
Chairman
David Marek
Chief Executive Officer
Frank Karbe
Chief Financial Officer
Matthew Lang
General Counsel
Address
Ste 1 3rd Fl, 11/12 St. James's Square
London
SW1Y 4LB
United Kingdom